{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T10:26:33Z","timestamp":1781000793152,"version":"3.54.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,1,18]],"date-time":"2019-01-18T00:00:00Z","timestamp":1547769600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,1,18]],"date-time":"2019-01-18T00:00:00Z","timestamp":1547769600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Osteoporos"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1007\/s11657-019-0561-x","type":"journal-article","created":{"date-parts":[[2019,1,18]],"date-time":"2019-01-18T20:02:35Z","timestamp":1547841755000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Serum 25-hydroxy-vitamin D and the risk of fractures in the teriparatide versus risedronate VERO clinical trial"],"prefix":"10.1007","volume":"14","author":[{"given":"Salvatore","family":"Minisola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Marin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Kendler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piet","family":"Geusens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiano A. F.","family":"Zerbini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis A.","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Casado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Fahrleitner-Pammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan J.","family":"Stepan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Lespessailles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00fcdiger","family":"Moericke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Bagur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e9ter","family":"Lakatos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"L\u00f3pez-Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Jacques","family":"Body","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,18]]},"reference":[{"key":"561_CR1","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/S0140-6736(17)32137-2","volume":"391","author":"DL Kendler","year":"2018","unstructured":"Kendler DL, Marin F, Zerbini CAF, Russo LA, Greenspan SL, Zikan V, Bagur A, Malouf-Sierra J, Lakatos P, Fahrleitner-Pammer A, Lespessailles E, Minisola S, Body JJ, Geusens P, M\u00f6ricke R, L\u00f3pez-Romero P (2018) Effects of teriparatide and risedronate on new fractures in postmenopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 391:230\u2013240. \nhttps:\/\/doi.org\/10.1016\/S0140-6736(17)32137-2","journal-title":"Lancet"},{"issue":"5","key":"561_CR2","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1002\/jbmr.3384","volume":"33","author":"P Geusens","year":"2018","unstructured":"Geusens P, Marin F, Kendler DL, Russo LA, Zerbini CAF, Minisola S, Body JJ, Lespessailles E, Greenspan SL, Bagur A, Stepan JJ, Lakatos P, Casado E, Moericke R, L\u00f3pez-Romero P, Fahrleitner-Pammer A (2018) Effects of teriparatide compared with risedronate on the risk of fractures in subgroups of postmenopausal women with severe osteoporosis: the VERO trial. J Bone Miner Res 33(5):783\u2013794. \nhttps:\/\/doi.org\/10.1002\/jbmr.3384","journal-title":"J Bone Miner Res"},{"issue":"12","key":"561_CR3","doi-asserted-by":"publisher","first-page":"4630","DOI":"10.1210\/jc.2007-0239","volume":"92","author":"B Dawson-Hughes","year":"2007","unstructured":"Dawson-Hughes B, Chen P, Krege JH (2007) Response to teriparatide in patients with baseline 25-hydroxyvitamin D insufficiency or sufficiency. J Clin Endocrinol Metab 92(12):4630\u20134636. \nhttps:\/\/doi.org\/10.1210\/jc.2007-0239","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"561_CR4","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1016\/j.bone.2012.02.635","volume":"50","author":"F Cosman","year":"2012","unstructured":"Cosman F, Dawson-Hughes B, Wan X, Krege JH (2012) Changes in vitamin D metabolites during teriparatide treatment. Bone 50(6):1368\u20131371. \nhttps:\/\/doi.org\/10.1016\/j.bone.2012.02.635","journal-title":"Bone"},{"key":"561_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/07435800.2018.1454461","volume":"13","author":"J Mok","year":"2018","unstructured":"Mok J, Brown C, Moore AEB, Min SS, Hampson G (2018) Skeletal response to treatment with teriparatide (TPD) after bisphosphonate in post-menopausal women with osteoporosis and a high prevalence of secondary risk factors in real-life setting of a metabolic bone clinic; effect of age and vitamin D status. Endocr Res 13:1\u20138. \nhttps:\/\/doi.org\/10.1080\/07435800.2018.1454461","journal-title":"Endocr Res"},{"issue":"9","key":"561_CR6","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1002\/jbmr.5650080915","volume":"8","author":"HK Genant","year":"1993","unstructured":"Genant HK, Wu CY, van Kuijk C, Nevitt MC (1993) Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8(9):1137\u20131148. \nhttps:\/\/doi.org\/10.1002\/jbmr.5650080915","journal-title":"J Bone Miner Res"},{"key":"561_CR7","first-page":"260","volume-title":"Dietary reference intakes for calcium and vitamin D","author":"Institute of Medicine (US) Committee to review dietary reference intakes for vitamin D and calcium","year":"2011","unstructured":"Institute of Medicine (US) Committee to review dietary reference intakes for vitamin D and calcium (2011) Dietary reference intakes for calcium and vitamin D. The National Academies Press, Washington DC, pp 260\u2013262"},{"issue":"5","key":"561_CR8","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1210\/jc.2014-4367","volume":"100","author":"JA Cauley","year":"2015","unstructured":"Cauley JA, Greendale GA, Ruppert K, Lian Y, Randolph JF Jr, Lo JC, Burnett-Bowie SA, Finkelstein JS (2015) Serum 25 hydroxyvitamin D, bone mineral density and fracture risk across the menopause. J Clin Endocrinol Metab 100(5):2046\u20132054. \nhttps:\/\/doi.org\/10.1210\/jc.2014-4367","journal-title":"J Clin Endocrinol Metab"},{"issue":"18","key":"561_CR9","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1056\/NEJM200505053521822","volume":"352","author":"AA Licata","year":"2005","unstructured":"Licata AA (2005) Osteoporosis, teriparatide, and dosing of calcium and vitamin D. N Engl J Med 352(18):1930\u20131931. \nhttps:\/\/doi.org\/10.1056\/NEJM200505053521822","journal-title":"N Engl J Med"},{"issue":"5","key":"561_CR10","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1007\/s00223-010-9414-8","volume":"87","author":"M Sridharan","year":"2010","unstructured":"Sridharan M, Cheung J, Moore AE, Frost ML, Fraser WD, Fogelman I, Hampson G (2010) Circulating fibroblast growth factor-23 increases following intermittent parathyroid hormone (1-34) in postmenopausal osteoporosis: association with biomarker of bone formation. Calcif Tissue Int 87(5):398\u2013405. \nhttps:\/\/doi.org\/10.1007\/s00223-010-9414-8","journal-title":"Calcif Tissue Int"},{"issue":"10","key":"561_CR11","doi-asserted-by":"publisher","first-page":"E1830","DOI":"10.1210\/jc.2014-1308","volume":"99","author":"H Alshayeb","year":"2014","unstructured":"Alshayeb H, Showkat A, Wall BM, Gyamlani GG, David V, Quarles LD (2014) Activation of FGF-23 mediated vitamin D degradative pathways by cholecalciferol. J Clin Endocrinol Metab 99(10):E1830\u2013E1837. \nhttps:\/\/doi.org\/10.1210\/jc.2014-1308","journal-title":"J Clin Endocrinol Metab"},{"key":"561_CR12","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.bone.2017.11.011","volume":"107","author":"C Ginsberg","year":"2018","unstructured":"Ginsberg C, Katz R, de Boer IH, Kestenbaum BR, Chonchol M, Shlipak MG, Sarnak MJ, Hoofnagle AN, Rifkin DE, Garimella PS, Ix JH (2018) The 24,25 to 25-hydroxyvitamin D ratio and fracture risk in older adults: the cardiovascular health study. Bone 107:124\u2013130. \nhttps:\/\/doi.org\/10.1016\/j.bone.2017.11.011","journal-title":"Bone"},{"issue":"7","key":"561_CR13","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1002\/jbmr.387","volume":"26","author":"CE Powe","year":"2011","unstructured":"Powe CE, Ricciardi C, Berg AH, Erdenesanaa D, Collerone G, Ankers E, Wenger J, Karumanchi SA, Thadhani R, Bhan I (2011) Vitamin D-binding protein modifies the vitamin D-bone mineral density relationship. J Bone Miner Res 26(7):1609\u20131616. \nhttps:\/\/doi.org\/10.1002\/jbmr.387","journal-title":"J Bone Miner Res"},{"issue":"2","key":"561_CR14","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.bone.2007.11.002","volume":"42","author":"NM Van Schoor","year":"2008","unstructured":"Van Schoor NM, Visser M, Pluijm SM, Kuchuk N, Smit JH, Lips P (2008) Vitamin D deficiency as a risk factor for osteoporotic fractures. Bone 42(2):260\u2013266. \nhttps:\/\/doi.org\/10.1016\/j.bone.2007.11.002","journal-title":"Bone"},{"issue":"11","key":"561_CR15","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1007\/s00198-005-1860-1","volume":"16","author":"P Gerdhem","year":"2005","unstructured":"Gerdhem P, Ringsberg KA, Obrant KJ, Akesson K (2005) Association between 25-hydroxy vitamin D levels, physical activity, muscle strength and fractures in the prospective population-based OPRA study of elderly women. Osteoporos Int 16(11):1425\u20131431. \nhttps:\/\/doi.org\/10.1007\/s00198-005-1860-1","journal-title":"Osteoporos Int"},{"issue":"11","key":"561_CR16","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1056\/NEJM199809103391104","volume":"339","author":"SR Cummings","year":"1998","unstructured":"Cummings SR, Browner WS, Bauer D, Stone K, Ensrud K, Jamal S, Ettinger B (1998) Endogenous hormones and the risk of hip and vertebral fractures among older women. Study of osteoporotic fractures research group. N Engl J Med 339(11):733\u2013738. \nhttps:\/\/doi.org\/10.1056\/NEJM199809103391104","journal-title":"N Engl J Med"},{"issue":"3","key":"561_CR17","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/j.bone.2006.09.026","volume":"40","author":"P Garnero","year":"2007","unstructured":"Garnero P, Munoz F, Sornay-Rendu E, Delmas PD (2007) Associations of vitamin D status with bone mineral density, bone turnover, bone loss and fracture risk in healthy postmenopausal women. The OFELY study. Bone 40(3):716\u2013722. \nhttps:\/\/doi.org\/10.1016\/j.bone.2006.09.026","journal-title":"Bone"},{"issue":"11","key":"561_CR18","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1093\/aje\/kwm210","volume":"166","author":"AW Roddam","year":"2007","unstructured":"Roddam AW, Neale R, Appleby P, Allen NE, Tipper S, Key TJ (2007) Association between plasma 25-hydroxyvitamin D levels and fracture risk: the EPIC-Oxford study. Am J Epidemiol 166(11):1327\u20131336. \nhttps:\/\/doi.org\/10.1093\/aje\/kwm210","journal-title":"Am J Epidemiol"},{"issue":"1","key":"561_CR19","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1359\/jbmr.071003","volume":"23","author":"AC Looker","year":"2008","unstructured":"Looker AC, Mussolino ME (2008) Serum 25-hydroxyvitamin D and hip fracture risk in older U.S. white adults. J Bone Miner Res 23(1):143\u2013150. \nhttps:\/\/doi.org\/10.1359\/jbmr.071003","journal-title":"J Bone Miner Res"},{"issue":"7","key":"561_CR20","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1210\/jc.2011-0385","volume":"96","author":"Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM; Endocrine Society","year":"2011","unstructured":"Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM; Endocrine Society (2011) Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96(7):1911\u20131930. \nhttps:\/\/doi.org\/10.1210\/jc.2011-0385","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Archives of Osteoporosis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11657-019-0561-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11657-019-0561-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11657-019-0561-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,4]],"date-time":"2020-06-04T08:05:26Z","timestamp":1591257926000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11657-019-0561-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,18]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["561"],"URL":"https:\/\/doi.org\/10.1007\/s11657-019-0561-x","relation":{},"ISSN":["1862-3522","1862-3514"],"issn-type":[{"value":"1862-3522","type":"print"},{"value":"1862-3514","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,18]]},"assertion":[{"value":"28 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Salvatore Minisola: Speaker and\/or consultant fees from: Abiogen, Amgen, DiaSorin, Lilly, Italfarmaco, Fujii, MSD, Takeda. Fernando Marin: Lilly Employee. David L. Kendler: Honoraria, research grants, and\/or consultant fees from: Amgen, Lilly, AstraZeneca, Astellas, UCB. Piet Geusens: Research support, consultant and\/or speaker fees from: Pfizer, Abbott, Lilly, Amgen, MSD, Roche, UCB, BMS, Novartis. Cristiano A.F. Zerbini: Research support from Lilly. Luis A. Russo: None. Enrique Casado: Speaker fees from: Amgen, Lilly. Astrid Fahrleitner-Pammer: Speaker fees from: Amgen, Alexion, BMS, Lilly, Fresenius. Jan J. Stepan: None. Eric Lespessailles: Speaker and consultant fees from: Amgen, Expanscience, Lilly, MSD; research grants from Abbvie, Amgen, Lilly, MSD, UCB. R\u00fcdiger M\u00f6ricke: None. Alicia Bagur: Speaker fees from Lilly and Craveri. P\u00e9ter Lakatos: None. Pedro L\u00f3pez-Romero: Lilly Employee. Jean Jacques Body: Speaker fee from Amgen; research support from Lilly.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"10"}}